Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2024 16:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the...
August 22, 2024 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium.
April 04, 2024 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

Travere to present abstracts at SIMD and GMDI highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for HCU